Charles H. Pippitt

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

Beth Y. Karlan, Amit M. Oza, Gary Richardson et al. · Journal of Clinical Oncology · 2011 · 225 citations · Full text

Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer

Ignace Vergote, Agustin A. García, John P. Micha et al. · Journal of Clinical Oncology · 2013 · 52 citations · Full text

Cisplatin-associated cortical blindness

Charles H. Pippitt, Hyman B. Muss, Howard D. Homesley et al. · Gynecologic Oncology · 1981 · 44 citations

Blindsight, Ophthalmology, Neuroanatomy +7

Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

Ignace Vergote, John P. Micha, Charles H. Pippitt et al. · Journal of Clinical Oncology · 2010 · 26 citations

Platinum-resistant/refractory Ovarian Cancer, Refractory Ovarian Cancer, Phase Ii +14

A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer

Ignace Vergote, Russell J. Schilder, Charles H. Pippitt et al. · Gynecologic Oncology · 2014 · 21 citations · Full text

Phase 1B, Pegylated Liposomal Doxorubicin, Medicine +8